Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

NCT01728181 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT01728181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01728181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
Lead sponsor
University of Utah
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 30, 2013
Completion date
March 31, 2016
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr unknown or wild-type, non-small cell lung cancer, stage iv disease